Epistatic hotspots organize antibody fitness landscape and boost evolvability.

Publication date: Jan 14, 2025

The course of evolution is strongly shaped by interaction between mutations. Such epistasis can yield rugged sequence-function maps and constrain the availability of adaptive paths. While theoretical intuition is often built on global statistics of large, homogeneous model landscapes, mutagenesis measurements necessarily probe a limited neighborhood of a reference genotype. It is unclear to what extent local topography of a real epistatic landscape represents its global shape. Here, we demonstrate that epistatic landscapes can be heterogeneously rugged and this heterogeneity may render biomolecules more evolvable. By characterizing a multipeaked fitness landscape of a SARS-CoV-2 antibody mutant library, we show that heterogeneous ruggedness arises from sparse epistatic hotspots, whose mutation impacts the fitness effect of numerous sequence sites. Surprisingly, mutating an epistatic hotspot may enhance, rather than reduce, the accessibility of the fittest genotype, while increasing the overall ruggedness. Further, migratory constraints in real space alleviate mutational constraints in sequence space, which not only diversify direct paths taken but may also turn a road-blocking fitness peak into a stepping stone leading toward the global optimum. Our results suggest that a hierarchy of epistatic hotspots may organize the fitness landscape in such a way that path-orienting ruggedness confers global smoothness.

Open Access PDF

Concepts Keywords
Biomolecules combinatorial mutagenesis
Fittest COVID-19
Increasing epistasis
Library Epistasis, Genetic
Mutant Evolution, Molecular
evolvability
Genetic Fitness
Genotype
heterogeneity
Humans
Mutation
SARS-CoV-2
sequence–function map

Semantics

Type Source Name
drug DRUGBANK Succimer
drug DRUGBANK Amino acids
drug DRUGBANK Huperzine B
disease IDO cell
drug DRUGBANK Spinosad
disease MESH COVID 19
drug DRUGBANK Albendazole
drug DRUGBANK Pentaerythritol tetranitrate
disease IDO site
disease MESH point mutations
drug DRUGBANK Flunarizine
drug DRUGBANK Trestolone
disease MESH influenza
disease MESH sti
drug DRUGBANK L-Arginine
drug DRUGBANK Aspartame
pathway REACTOME Translation
drug DRUGBANK Coenzyme M
disease IDO antibiotic resistance
drug DRUGBANK Methionine
pathway REACTOME Protein folding
disease IDO protein
disease IDO host
drug DRUGBANK Isoxaflutole
disease IDO process

Original Article

(Visited 1 times, 1 visits today)